Peer-Reviewed · Quarterly

Journal of Pharmacy Practice and Community Medicine

Peer-Reviewed · Open Access

Journal of Pharmacy Practice and Community Medicine (JPPCM) is an international peer-reviewed journal. JPPCM publishes four issues per year devoted to research and review articles in the field of pharmacy practice, community medicine and related discipline of health sciences. JPPCM aims at facilitating the development of community-based research, education, and health care services.

Editorial board

Akram Ahmad, BPharm, PharmD, (PhD)
Founding Editor and Editor-in-Chief
Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia
Muhammad Umair Khan, MS, (PhD)
Executive Editor
Faculty of Pharmacy, The University of Sydney, Australia
Fahad Saleem, PhD
Section Editor
Department of Pharmacy Practice, Faculty of Pharmacy & Health Sciences, University of Baluchistan, Pakistan
Vijay Kumar Chattu, MBBS, MD, MPH, (PhD)
Section Editor
Unit of Public Health and Primary Care, Faculty of Medical Sciences, University of the West Indies, Trinidad and Tobago
Abhishek Sharma, BPharm, MPH
Associate Editor
Department of Global Health, Center for Global Health and Development, Boston University School of Public Health, Boston University, MA 02118, Boston, USA
Shiva Raj Mishra, BPH, MPH, (PhD)
Associate Editor
Department of Epidemiology and biostatistics, School of Public Health, University of Queensland, Brisbane, Australia
Uday Venkat Mateti, PhD
Associate Editor
Department of Pharmacy Practice, School of Pharmacy, Nitte University, Mangalore, India
Isha Patel, PhD
Managing Editor
Department of Pharmacy Practice, Administration and Research, Marshall University School of Pharmacy (MUSOP), Marshall University, Huntington, WV 25755, USA
Niraj Kumar, PhD (Biostatistics)
Statistical Advisor
Department of Statistics, Amity Institute of Applied Sciences, Amity University, Noida, India
Rajesh Balkrishnan, PhD
Editorial Board Member
Department of Public Health Sciences, University of Virginia School of Medicine, USA
Mohamed Izham B. Mohamed Ibrahim, PhD
Editorial Board Member
Professor of Social & Administrative Pharmacy, College of Pharmacy, Qatar University, Doha, Qatar
Zaheer-Ud-Din Babar, PhD
Editorial Board Member
Professor in Medicines and Healthcare, Department of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom

Editors' Choice · Review Article

Exploring Pathogenesis, Clinical Manifestations, and Management of Human Metapneumovirus Infection

Gaurao Damre, Snehal Sathe, Dhanashree Shinde, Vaibhav V Bhone

Human Metapneumovirus (HMPV), identified in 2001, is an emerging respiratory virus. Within the Pneumoviridae family, genus Metapneumovirus. This RNA virus is now recognised as a substantial cause of both upper along lower Respiratory Tract Infections (RTIs), affecting individuals belonging to all ages. While this virus may impact healthy adults, the most vulnerable populations include young children, infants, elderly adults, as well as immunocompromised individuals. Pathophysiology of HMPV involves its entry into respiratory epithelial cells, facilitated by viral Fusion (F), attachment (G) proteins. After entering the host cell, HMPV replicates in the cytoplasm, leading to the production of new virions that further propagate the infection. Both innate along adaptive components are essential to the complicated immune response to HMPV. Innate immunity, including pattern recognition receptors and natural killer cells, provides the first line of defence, while the adaptive immune response, consisting of T cells, antibodies, and B cells, is responsible for clearing the virus and offering long-term immunity. However, in severe cases, immune responses may contribute to lung injury, airway remodelling, and fibrosis, especially in individuals with pre-existing conditions or those experiencing prolonged infections. Clinically, HMPV infection varies from mild symptoms like cough, fever, as well as sore throat to more severe manifestations, for example, pneumonia, bronchiolitis, and respiratory failure. Supportive care, which includes hydration, is the main emphasis of management and rest, though antiviral treatments, for example, intravenous immunoglobulin, ribavirin, along with monoclonal antibodies, may be considered in severe cases.

Read Full Text PDFDOI: 10.5530/jppcm.20260049